Summary:
In children and adults with type 1 diabetes (T1D), automated insulin delivery (AID) using MiniMed™ 670G or 770G systems significantly improved HbA1c and reduced time spent in hypoglycemia compared to multiple daily injections (MDI) with or without continuous glucose monitoring, though it was associated with no major increase in severe hypoglycemia or diabetic ketoacidosis rates.
| PICO | Description |
|---|---|
| Population | Children and adults aged 2–80 years diagnosed with type 1 diabetes, classified into two subgroups based on baseline HbA1c levels (>8.0% and ≤8.0%), across 32 international centers. |
| Intervention | Automated insulin delivery (AID) using MiniMed™ 670G or 770G insulin pump systems over a 6-month period. |
| Comparison | Multiple daily injections (MDI) with or without continuous glucose monitoring (CGM). |
| Outcome | AID significantly reduced HbA1c by a mean of -0.7% (95% CI: -1.1 to -0.3, P = 0.0002) in participants with baseline HbA1c >8.0%, and decreased %TBR <70 mg/dL by 4.8% (95% CI: -6.4 to -3.1, P<0.001) for those with baseline HbA1c ≤8.0%. Severe hypoglycemia and DKA rates were low and within safety targets. |
Source: Jendle, Johan H., et al. “Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.” Read article here.
